TREATMENT WITH IMETELSTAT PROVIDES DURABLE TRANSFUSION...

HemaSphere 2019 / 06 Vol. 3

TREATMENT WITH IMETELSTAT PROVIDES DURABLE TRANSFUSION INDEPENDENCE (TI) IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER RISK MDS (LR-MDS) RELAPSED/REFRACTORY (R/R) TO ERYTHROPOIESIS STIMULATING AGENTS (ESAS)

Fenaux, P., Steensma, D. P., Van Eygen, K., Raza, A., Santini, V., Germing, U., Font, P., Díez-Campelo, M., Thepot, S., Vellenga, E., Patnaik, M. M., Jang, J. H., Sherman, L., Sun, L., Varsos, H., Ri
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
3
Journal:
HemaSphere
DOI:
10.1097/01.hs9.0000561628.96745.54
Date:
June, 2019
File:
PDF, 416 KB
2019
Conversion to is in progress
Conversion to is failed